PD-L1 inhibitor

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
Andrea Ardizzoni, Sergio Azevedo, Belen Rubio-Viqueira, Delvys Rodríguez-Abreu, Jorge Alatorre-Alexander, Hans J M Smit, Jinming Yu, Konstantinos Syrigos, Kerstin Trunzer, Hina Patel, Jonathan Tolson, Andres Cardona, Pablo D Perez-Moreno, Tom Newsom-Davis

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001865; DOI: 10.1136/jitc-2020-001865
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 8; DOI: 10.1186/s40425-018-0316-z

Main menu